Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Inclusion criteria: * Type 2 Diabetes Mellitus. * Admitted to the hospital, or urgent heart failure visit for worsening heart failure. * Prior diagnosis of heart failure (\> 3 months). * Prior chronic treatment for heart failure with a loop diuretic (eg furosemide, torsemide, bumetanide) for \> 30 days. * Randomized when hemodynamically stable, prior to hospital discharge or within 3 days of discharge. * Brain natriuretic peptide (BNP) ≥150 picograms per milliliter (pg/mL) (≥450 pg/mL for participants with atrial fibrillation) or N-terminal B-type natriuretic peptide ≥600 pg/mL (≥1800 pg/mL for participants with atrial fibrillation). * Participants with Left Ventricular Ejection Fraction \<40% should be on beta-blockers and renin-angiotensin-aldosterone system (RAAS) inhibitors as per local guidelines unless contraindicated. * Signed written informed consent. Exclusion criteria: * Age \< 18 years or \> 85 years. * Worsening heart failure attributed to other causes such as pulmonary embolism, stroke, heart attack. * Cardiac surgery or coronary procedure within 1 month or planned during study. * Lower extremity complications (such as skin ulcer, infection, osteomyelitis, and gangrene) identified during screening and requiring treatment at randomization. * Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during the study. * Acute coronary syndromes within 3 months prior to Randomization. * Hemodynamically significant uncorrected primary valvular disea…